The process of better understanding the brain is like building a puzzle whose pieces grow in number over time.
In a paper published in Nature Neuroscience, researchers pushed the science forward on our reward pathways.
The key to overcoming addictions and psychiatric disorders lives deep inside the netherworld of our brains and the circuitry that causes us to feel good. Just like space, this region of the brain needs more exploration.
The oldest and most known reward pathway is the mesolimbic dopamine system, which is composed of neurons projecting from the ventral tegmental area (VTA) to the nucleus accumbens — a key structure in mediating emotional and motivation processing,
Dopamine is a neurotransmitter that is released when the brain is expecting reward. A spike in dopamine could come be from eating pizza, dancing, shopping and sex. But it can also come from drugs, and lead to substance abuse.
In the search for new therapies to treat addiction and psychiatric illness, researchers are examining pathways beyond dopamine that could play a role in reward and reinforcement.
In a paper published in Nature Neuroscience, researchers from the Bruchas Lab at UW Medicine pushed the science forward on our reward pathways and found another such pathway.
“This study opens new avenues to understanding reward circuitry that might be altered in abuse of nicotine, opiates or other drugs as well as neuropsychiatric diseases that affect reward processing including depression,” said corresponding author Dr. Michael Bruchas, professor of anesthesiology and pain medicine at the University of Washington School of Medicine.
The researchers found that approximately 30% of cells in the VTA – the midbrain – are GABA neurons. Neurons are the fundamental units of the brain and nervous system, the cells responsible for receiving sensory input from the external world, for sending motor commands to our muscles, and for transforming and relaying the electrical signals at every step in between.
VTA GABA neurons have increasingly been recognized as involved in reward and aversion, as well as potential targets for the treatment of addiction, depression and other stress-linked disorders.
“What we found are unique GABAergic cells that project broadly to the nucleus accumbens, but projections only to a specific portion contribute to reward reinforcement,” said co-lead author Raajaram Gowrishankar, a postdoctoral scholar in the Bruchas Lab and the Center for the Neurobiology of Addiction, Pain and Emotion.
In male and female mice, researchers showed that long-range GABA neurons from the VTA to the ventral, but not the dorsal, nucleus accumben shell are engaged in reward and reinforcement behavior. They showed that this GABAergic projection inhibit cholinergic interneurons – key players in reward-related learning.
These findings “further our understanding of neuronal circuits that are directly implicated in neuropsychiatric conditions such as depression and addiction,” the researchers wrote.
Gowrishankar said the findings are allowing scientists to understand subregions of the brain and to visualize how specific neuromodulators are released during reward processing. In science terms, the researchers were able to highlight heterogeneity, or differences, in the brain.
“It’s really important that we don’t think of structures in the brain as monolithic,” said Gowrishankar. “There’s lots of little nuance in brain – how plastic it is, how it’s wired. This finding is showing one way how differences can play out.”
Reference: “Ventral tegmental area GABAergic inhibition of cholinergic interneurons in the ventral nucleus accumbens shell promotes reward reinforcement” by Ream Al-Hasani, Raajaram Gowrishankar, Gavin P. Schmitz, Christian E. Pedersen, David J. Marcus, Sofia E. Shirley, Taylor E. Hobbs, Abigail J. Elerding, Sophie J. Renaud, Miao Jing, Yulong Li, Veronica A. Alvarez, Julia C. Lemos and Michael R. Bruchas, 12 August 2021, Nature Neuroscience.
DOI: 10.1038/s41593-021-00898-2
This research was funded by grants R00 DA038725, F31 DA051124, R37 DA033396, P30 DA048736 from the National Institutes of Health and National Institute on Drug Abuse.